Can Metabolic Vulnerabilities in Tumors be Therapeutically Exploited?
Tuesday April 24, 2018
9:30 am
-
12:00 pm
Eastern Time (ET)
Room 15A
DCP
MP
TCP
Chair :
Susan Cole
Queen's University at Kingston
Koen van de Wetering
Thomas Jefferson University
Many metabolic pathways are altered in cancer cells, which sometimes rely heavily on specific nutrients. Significant progress has been made in recent years in our understanding of how these metabolic changes may lead to vulnerabilities in different tumor types that may be harnessed for therapeutic benefit. This symposium will provide insights into the strategies used to identify these vulnerabilities and how they may be exploited in anticancer therapy.
Speakers
Gary Siuzdak
- The Scripps Research Institute
Modulating the Oncogenic Phenotype with Metabolites
Heather Christofk
- University of California, Los Angeles
Metabolic Transitions in Cancer: Lessons from Viral Infection
Boyi Gan
- The University of Texas MD Anderson Cancer Center
The Glutamate/Cystine Antiporter SLC7A11/xCT Regulates Glucose Dependency in Cancer Cells: Mechanism and Therapeutic Implications
Koen van de Wetering
- Thomas Jefferson University
ABBC5: A Multidrug Efflux Transporter with an Unusual Substrate Spectrum
Heather True
- School of Pharmacy, Pacific University Oregon
Raloxifene Compromises Mitochondria, Induces ROS Stress and the Unfolded Protein Response, and Synergizes Gemcitabine's Cytotoxicity in Pancreatic Cancer Cells
Bettine Gibbs
- Butler University
Molecular Targeting and Inactivation of Glutaminase and CDK4/6 in Mantle Cell Lymphoma